您的位置: 首页 > 农业专利 > 详情页

Buffered Formulations Of Exendin (9-39)
专利权人:
Eiger BioPharmaceuticals, Inc.;The Board of Trustees of the Leland Stanford Junior University
发明人:
Xiaofeng Xiong,Debra Odink,Colleen M. Craig,Christine M.N. Smith
申请号:
US16461329
公开号:
US20200069802A1
申请日:
2017.11.21
申请国别(地区):
US
年份:
2020
代理人:
摘要:
Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充